Federal Register #2026-14966

NIH Seeks Licensing and Co-Development Partners for Ebola Vaccine and AML T Cell Therapy Technologies

The National Institutes of Health (NIH), through the National Institute of Allergy and Infectious Diseases (NIAID) and the National Cancer Institute (NCI), is seeking partners for licensing and co-development of two government-owned biomedical inventions: - Government Buyer: - National Institutes of Health (NIH) - Sub-agencies: National Institute of Allergy and Infectious Diseases (NIAID), National Cancer Institute (NCI) - OEMs/Inventors: - NIH (as the technology originator) - NIAID and NCI as the developing institutes - Products/Technologies Available: - Replication-Competent VSVBDBV Vaccine for Bundibugyo Virus - Part number: E12220260 - Includes recombinant rVSVBDBV vaccine and DNA plasmid pATX VSVDGBDBV GP - Designed for rapid immune response and post-exposure protection with a single dose - NPM1 Mutation-Specific T Cell Receptors (TCR6 and TCR7) for AML Treatment - Part number: E20020250 - T cell receptors targeting the mutant NPM1 neoepitope AVEEVSLRK in the context of HLAA*11:01 - Intended for adoptive cell therapy in acute myeloid leukemia (AML) - Unique/Notable Requirements: - Technologies are at the pre-clinical development stage - Available for commercial licensing and collaborative research - Access to unpublished information requires a signed Confidential Disclosure Agreement - Emphasis on rapid outbreak response, improved safety, and high specificity for targeted therapies

Description

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), Department of Health and Human Services (HHS), announces the availability of government-owned inventions for licensing. These inventions result from federally funded research and development and include technologies such as a replication-competent VSVBDBV vaccine for rapid prevention and post-exposure protection against Bundibugyo virus. The notice invites licensing and collaborative research opportunities to commercialize these technologies and extend market coverage, including foreign patent applications on selected inventions.

View original listing